click below
click below
Normal Size Small Size show me how
ID Quiz 2
| Generic | Brand | Drug Class | Indication | MOA | AE | C/I | BBW | ROA |
|---|---|---|---|---|---|---|---|---|
| Ampicillin + Sulbactam | Unasyn | Pencillin, antibiotic | Bacterial Infections | Inhibits bacterial cell wall synthesis | Allergy to any beta-lactam abx, mononucleosis, hypersensitivity rxn, caution in liver impairment due to reported hepatotoxicity | IM, IV | ||
| Cefazolin | Ancef | Cephalosporin , 1st gen | Biliary tract, bloodstream, bone and genital, respiratory tract, skin and soft tissue, and urinary tract infections. Endocarditis tx. Surgical prophylaxis | Inhibits bacterial cell wall synthesis | Caution in patients with hx of seizure, high levels - particularly in renal impairment - may increase risk, or hypersensitivity to beta-lactams or PCNs | IM, IV | ||
| Cefepime | Maxipime | Cephalosporin, 4th gen | Intra-abdominal infection, neutropenic fever, mod-severe pneumonia, skin and soft tissue infection, complicated UTI | Inhibits bacterial cell wall synthesis | Severe neurologic rxns, including seizures and nonconvulsive status. Risk may be increased with renal impairment. Hypersensitivity to PCNs or beta-lactams | IM, IV | ||
| Cefoxitin | Mefoxin | Cephalosporin, 2nd gen | Sepsis, surgical prophylaxis, and bloodstream, bone and joint, gynecological, intraabdominal, lower respiratory tract, skin and soft tissue, and urinary tract infections. | Inhibits bacterial cell wall synthesis | Pts <3 mo, higher doses associated with eosinophilia and elevated AST | IM, IV | ||
| Ceftriaxone | Rocephin | Cephalosporin, 3rd gen | Bloodstream, bone and joint, uncomplicated gonococcal, mild-mod intra-abdominal, lower respiratory tract, skin and soft tissue, and complicated urinary tract infections. Bacterial meningitis, acute otitis media, colorectal surgical prophylaxis | Inhibits bacterial cell wall synthesis | Hyperbilirubinemic neonates, concurrent use with IV calcium containing solutions in neonates | IM, IV | ||
| Cefuroxime | Zinacef, Ceftin | Cephalosporin, 2nd gen | Bone and joint, lower respiratory tract, skin and structure infections (impetigo), and urinary tract infections. Acute COPD exacerbation, early Lyme disease, acute otitis media, septicemia, acute bacterial sinusitis, group A strep, & surgical prophylaxis | Inhibits bacterial cell wall synthesis | Tablets and oral suspension not 1:1. Hypersensitivity to beta-lactams | IM, IV | ||
| Clarithromycin | Biaxin | Macrolide antibiotic | Acute exacerbation of COPD, H. pylori eradication, mycobacterial (non-TB) infection, otitis media, CAP, acute bacterial rhinosinusitis, skin/skin structure infection, or group A streptococcal pharyngitis | Binds to 50S ribosomal subunit, resulting in inhibition of protein synthesis | Potentially significant interactiosn may exist with CYP3A4 metabolism, including some statins. Hx of QT prolongation or ventricular arrhythmias. | Oral | ||
| Fidaxomicin | Dificid | Macrolide antibiotic | C. diff | Inhibits RNA polymerase sigma subunit resulting in inhibition of protein synthesis | Do not use for systemic inefctions, absorption is negligible | Oral | ||
| Gentamicin | Garamycin | Aminoglycoside antibiotic | Serious, dermatologic or ophthlamic infections | Inhibits protein synthesis | D/c if nephrotoxicity | May cause neurotoxicity such as neuromuscular blockade and respiratory paralysis, especially when given after anesthesia or NM blockers. Risk factors include pre-existing renal impairment, concomitant nephrotoxic med, advanced age, dehydration. | IM, IV, ophthalmic, topical | |
| Imipenem + Cilastatin | Primaxin | Carbapenem antibiotic | Gram-negative bactermia blood stream, bone and joint, gynecologic, intra-abdominal, mod-severe skin and soft tissue, and urinary tract infections. Endocarditis and penumonia. | Inhibits bacterial cell wall synthesis | CNS adverse effects including confusional states and seizures (myclonic). May decrease serum conc of divalproex | IV | ||
| Linezolid | Zyvox | Oxazolidinone | Vancomycin resistant enterococcal infections, pneumonia, and skin and skin structure infections | Binds to 23S ribosomal RNA of 50S subunit | Avoid use in patients with other serotonergic drugs which may reduce linezolid's metabolism unless clinically appropriate and under close monitoring. | IV, oral | ||
| Meropenem | Merrem | Carbapenem antibiotic | Intra-abdominal infection, bacterial meningitis, mod-severe skin and skin structure infection | Inhibits bacterial cell wall synthesis | Use with caution in pts with renal impairment. Increased risk of seizure and thrombocytopenia have been reported in pts with renal impairment. Dosage adj required with CrCl <50 mL/min. | IV | ||
| Moxifloxacin | Fluoroquinolone antibiotic | Mild-moderate CAP, bacterial conjunctivitis | Inhibits DNA gyrase, topoisomerase IV | avoid use in pts who experience serious adverse reactions of tendonitis, tendon rupture, etc. | May increase risk of tendonitis, tendon rupture, peripheral neuropathy, and CNS effects. | IV, ophthalmic | ||
| Penicillin V Potassium | Pen VK | Penicillin antibiotic | Erysipelas, acute simple plaque-associated gingivitis, pneumococcal infections, group A streptococcus, group A pharyngitis streptococcus | Inhibits bacterial cell wall synthesis | Prolonged use may result in fungal or bacterial superinfection | Oral | ||
| Piperacillin + Tazobactam | Zosyn | Penicillin antibiotic | Intra-abdominal infections, pelvic infection, CAP, skin and soft tissue infection | Inhibits bacterial cell wall synthesis | Hypersensitivity to PCNs or beta-lactams. Risk of nephrotoxicity increased when given w/ vanco. | IV | ||
| Tobramycin | Tobradex | Aminoglycoside antibiotic | Bloodstream infections, bone infections, intra-abdominal infections, bacterial meningitis, pneumonia, skin and skin structure infections, complicated UTI | Inhibits protein synthesis | D/c if signs of nephrotoxicity, ototoxicity | May cause nephrotoxicity, neuromuscular blockade, respiratory paralysis, ototoxicity (tinnitus or vertigo) | IM, IV, ophthalmic, oral inhalation | |
| Vancomycin | Vancocin, Firvanq | Glycopeptide antibiotic | C. diff, endocarditis, enterocolitis, staphylococcal infection | Blocks glycopeptide polymerization through binding tightly to D-alanyl-D-alanine portion of cell wall precursor | Solutions containing dextrose may be C/I in patients with allergy to corn or corn products. | The formulation containing the excipients PEG 400 and NADA is not recommended for use during pregnancy due to fetal malformations in animal studies. | IV |